This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.04.073v1 48/3/516    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Schroeder, C. Articles by Jordan, J. Search for Related Content PubMed PubMed Citation Articles by Schroeder, C. Articles by Jordan, J.

CLINICAL RESEARCH: AUTONOMIC FUNCTION

Norepinephrine Transporter Inhibition Prevents Tilt-Induced Pre-Syncope

Christoph Schroeder, MD^_*, Andreas L. Birkenfeld, MD^_*, Antje F. Mayer^_*, Jens Tank, MD^_*, Andre Diedrich, MD, PhD, Friedrich C. Luft, MD^_* and Jens Jordan, MD^_*,_*

^_* Franz-Volhard Clinical Research Center, Medical Faculty of the Charité and HELIOS Klinikum, Berlin, Germany
Autonomic Dysfunction Service, Vanderbilt University, Nashville, Tennessee.

Manuscript received January 25, 2006; revised manuscript received March 10, 2006, accepted April 10, 2006.

^_* Reprint requests and correspondence: Dr. Jens Jordan, Franz-Volhard Clinical Research Center, Charité Campus Buch, Wiltbergstr. 50, Haus 129, 13125 Berlin, Germany. (Email: jordan{at}fvk.charite-buch.de).

OBJECTIVES: We tested the hypothesis that pharmacological norepinephrine reuptake transporter (NET) inhibition delays the onset of head-up tilt-induced presyncope in healthy subjects.

BACKGROUND: Treatment of neurally mediated syncope is unsatisfactory. In a previous study in a small number of healthy subjects, pharmacologic NET inhibition delayed the onset of head-up tilt-induced pre-syncope.

METHODS: We combined data sets from 3 substudies comprising 51 healthy subjects without a history of syncope. In a double-blind, randomized, cross-over fashion, subjects underwent 2 head-up tilt tests, once with placebo and once with a NET inhibitor (sibutramine or reboxetine). Tilt testing was prematurely ended when pre-syncopal symptoms such as dizziness, nausea, or visual disturbances occurred together with a decrease in blood pressure and/or heart rate.

RESULTS: The mean tolerated tilt test duration was 29 ± 2 min with placebo and 35 ± 1 min with NET inhibition (p = 0.001). The odds ratio for premature abortion of head-up tilt testing was 0.22 (95% confidence interval 0.09 to 0.55, p < 0.001) in favor of NET inhibition. Norepinephrine reuptake transporter inhibition elicited a pressor response and increased upright heart rate.

CONCLUSIONS: In healthy subjects, NET inhibition prevents tilt-induced neurally mediated (pre)syncope. Therefore, NET inhibition may be a worthwhile target of drug intervention for larger trials in highly symptomatic patients with neurally mediated syncope.

Abbreviations and Acronyms   DHPG = dihydroxyphenylglycol   HR = heart rate   NET = norepinephrine reuptake transporter

This article has been cited by other articles:

				S. Carew, M. O. Connor, J. Cooke, R. Conway, C. Sheehy, A. Costelloe, and D. Lyons A review of postural orthostatic tachycardia syndrome Europace, January 1, 2009; 11(1): 18 - 25. [Abstract] [Full Text] [PDF]

				S. Strempel, C. Schroeder, R. Hemmersbach, A. Boese, J. Tank, A. Diedrich, M. Heer, F. C. Luft, and J. Jordan Norepinephrine transporter inhibition alters the hemodynamic response to hypergravitation J Appl Physiol, March 1, 2008; 104(3): 756 - 760. [Abstract] [Full Text] [PDF]